Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Immune Response Following Administration of Zoster Vaccine to Subjects With Rheumatoid Arthritis Receiving Tofacitinib (CP-690,550) Or Placebo With Background Methotrexate Treatment

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Immune Response Following Administration of Zoster Vaccine to Subjects With Rheumatoid Arthritis Receiving Tofacitinib (CP-690,550) Or Placebo With Background Methotrexate Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tofacitinib (Primary) ; Varicella zoster virus vaccine
  • Indications Rheumatoid arthritis
  • Focus Pharmacodynamics
  • Sponsors Pfizer

    • Most Recent Events

    • 14 Nov 2018 Results assessing Short-, Mid-, and Long-term Effects of Tofacitinib on Lymphocytes in RA patients using data from NCT00853385, NCT01039688, NCT00147498, NCT00413660, NCT00550446, CT02147587 and NCT00413699 sub-studies), published in the Arthritis and Rheumatology
    • 08 Nov 2017 Results of pooled data from two trial (NCT02147587 and NCT00413699) assessing evaluate the long-term effectiveness of LZV in patients with RA, via the incidence of HZ after treatment with tofacitinib for up to 27 months, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 28 Aug 2017 Results published in the Arthritis and Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top